Intended only for Healthcare Professionals in Great Britain
Mounjaro® (tirzepatide)
Prescribing InformationMounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise1
- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes
Mounjaro is indicated for weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of1
- ≥ 30 kg/ m2 (obesity) or
- ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).
The first and only licensed GIP and GLP-1 receptor agonist 1,2 *
Resources
Mounjaro Factsheet
Patient Guide to Mounjaro for Type 2 Diabetes
We have a guide which will provide your patients with important information about the initiation and use of Mounjaro® in a KwikPen® for Type 2 diabetes.
Mounjaro 2.5 mg KwikPen - shelf-life extension
Based on Lilly’s submission of additional stability data, the MHRA have approved an extension to the shelf-life of specific batches of Mounjaro 2.5 mg KwikPen. The Dear HCP Letter and Patient Letters are accessible via the below links and they provide an overview of the affected batches, as well as further information to help you support patients who have been supplied these batches.
Request a Lilly representative
* GIP= glucose-dependent insulinotropic polypetide; GLP-1 = glucagon-like-peptide-1
- Mounjaro Summary of Product Characteristics
- Willard FS et al. Tirzepatide is an imbalanced and biased GIP and GLP-1 recpetor agonist. JCI Insight 2020; 5(17): e140532
PP-TR-GB-0446 April 2024
KwikPen® is a registered trademark of Eli Lilly and Company